TOPAZ-1 Post Hoc Analysis Supports Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer

A post hoc analysis of the TOPAZ-1 clinical trial indicates that the combination of durvalumab and chemotherapy provides a survival benefit for patients with advanced biliary tract cancer, regardless of their PD-L1 expression levels. According to reporting by The ASCO Post, these findings suggest that the immunotherapy benefit extends across various patient subgroups, supporting the use of the regimen as a standard approach for this malignancy.

Biliary tract cancers, which include cancers of the bile ducts and gallbladder, often present at advanced stages and have historically responded poorly to standard chemotherapy. The TOPAZ-1 trial sought to determine if adding durvalumab, a PD-L1 blocking antibody, to a chemotherapy backbone of gemcitabine and cisplatin would improve patient outcomes.

The primary objective of the post hoc analysis was to evaluate whether the efficacy of the durvalumab plus chemotherapy combination varied based on the expression of programmed death-ligand 1 (PD-L1) on tumor cells. PD-L1 is often used as a biomarker to predict which patients are most likely to respond to immune checkpoint inhibitors.

Durvalumab Efficacy Across PD-L1 Expression Levels

The analysis revealed that the combination therapy outperformed chemotherapy alone across all tested levels of PD-L1 expression. According to The ASCO Post, the data showed that patients did not need high levels of PD-L1 to derive a clinical benefit from the addition of durvalumab.

This finding is significant because it suggests that PD-L1 testing may not be a necessary prerequisite for prescribing the durvalumab combination in advanced biliary tract cancer. In many other cancer types, high PD-L1 expression is a primary indicator for the use of immunotherapy, but the TOPAZ-1 data indicates a broader utility for this specific regimen.

Trial Design and Clinical Outcomes

The TOPAZ-1 trial was a randomized, double-blind, phase 3 study. Participants were assigned to receive either durvalumab combined with gemcitabine and cisplatin or a placebo combined with the same chemotherapy regimen.

The results showed an improvement in overall survival (OS) and progression-free survival (PFS) for the group receiving the immunotherapy combination. These outcomes were consistent across different demographics and disease characteristics, reinforcing the stability of the treatment’s effect.

The use of gemcitabine and cisplatin as the chemotherapy backbone is a long-standing approach for biliary tract cancers, but the addition of durvalumab aims to activate the patient’s own immune system to recognize and attack the tumor cells more effectively.

Clinical Implications for Advanced Biliary Tract Cancer

Biliary tract cancers are characterized by a low mutation rate compared to some other solid tumors, which often makes them less responsive to immunotherapy. The success of the TOPAZ-1 regimen provides a verified pathway for improving survival in a patient population with limited options.

By demonstrating that the benefit is not limited to PD-L1-high patients, the analysis supports a wider application of the therapy. This reduces the reliance on a single biomarker that may not fully capture the immune environment of biliary tract tumors.

The findings contribute to the evolving standard of care for advanced biliary tract cancer, shifting the focus toward combination therapies that pair cytotoxic drugs with immune checkpoint inhibitors to maximize the probability of tumor shrinkage and extended life expectancy.